Characteristics of receptors for dopamine in the pars intermedia of the amphibian Xenopus laevis.
While mammalian dopamine receptors have been extensively characterized, very little attention has been given to these receptors in lower vertebrates. Dopamine is thought to be a physiologically important melanotropin release-inhibiting factor in amphibians. By administering selective dopamine receptor agonists and antagonists to superfused neurointermediate lobes of Xenopus laevis and monitoring their effect on the release of melanophore-stimulating hormone (MSH), we have examined the characteristics of the receptors involved in the dopamine-induced inhibition of MSH secretion. The results show that the receptor system involved has characteristics of both classical D-2 receptors and alpha-adrenergic receptors. This is concluded from: the agonistic effect of both the D-2 receptor agonists LY-171555 and apomorphine; the antagonism of this effect, not only by the D-2 receptor antagonists sulpiride, domperidon and haloperidol, but also by the alpha-adrenergic receptor antagonist phentolamine, and the observation that the effect of adrenaline, which is extremely potent in inhibiting MSH release, could be fully blocked by D-2 receptor antagonists. Both the fact that the dopamine-induced inhibition of MSH secretion could not be blocked by haloperidol, domperidon and phentolamine, and that adrenaline-induced inhibition was hardly blocked by phentolamine, led us to suggest the possible presence of multiple receptors or receptor sites. We find no evidence for the involvement of dopamine D-1 receptors in the regulation of MSH release. The effects of dopamine agonists and antagonists were also studied in vivo by monitoring changes in pigment dispersion of dermal melanophores. The results are consistent with our in vitro findings and indicate, moreover, that in the living animals there must also be a non-catecholaminergic system involved in the inhibition of MSH release from the pars intermedia.
D000818:Animals; D001058:Apomorphine / Q000494:pharmacology; D001549:Benzamides / Q000494:pharmacology; D004294:Domperidone / Q000494:pharmacology; D004298:Dopamine / Q000494:pharmacology; D004347:Drug Interactions; D004873:Ergolines / Q000494:pharmacology; D006220:Haloperidol / Q000494:pharmacology; D009074:Melanocyte-Stimulating Hormones / Q000378:metabolism*; D010903:Pituitary Gland, Anterior / Q000502:physiology*; D019257:Quinpirole; D011954:Receptors, Dopamine / Q000502:physiology*; D013469:Sulpiride / Q000494:pharmacology; D014982:Xenopus laevis
D001549:Benzamides; D004873:Ergolines; D011954:Receptors, Dopamine; D019257:Quinpirole; D004294:Domperidone; D013469:Sulpiride; D009074:Melanocyte-Stimulating Hormones; D006220:Haloperidol; D001058:Apomorphine; C030265:nemonapride; D004298:Dopamine